Treasury’s Outbound Investment Rule Could Send China-Origin Biotech Deals, and U.S. Jobs, to Europe October 26, 2026 To be submitted […]
Podcast: Play in new window | Download (Duration: 11:52 — 27.2MB)
Subscribe: Apple Podcasts | Spotify | RSS
No megadeals, no retreat: China’s average deal fell to $1.7B, but it still holds 58% of global licensing value. In
Podcast: Play in new window | Download (Duration: 12:13 — 28.0MB)
Subscribe: Apple Podcasts | Spotify | RSS
M&A has already topped all of 2025, and China still holds 58% of global licensing value. In Episode 38 of
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q3 Market Conditions Report applies the latest data to analyze the current landscape in life sciences deals.
Locust Walk examined the global dual-targeting (bi-/multi-specific, fusion protein, etc.) biologics pipeline in immunology & inflammation, from target-pair competitive density to BD deal trends and valuation benchmarks, to assess where the next wave of I&I partnering opportunity lies.
Why biopharma licensing, partnership, and M&A share one path to leverage. Locust Walk’s latest white paper makes the case that licensing, partnerships, and M&A aren’t separate playbooks. They’re one continuum, and the leverage that shapes a deal’s final terms is built (or lost) long before a term sheet appears.
Podcast: Play in new window | Download (Duration: 9:15 — 21.2MB)
Subscribe: Apple Podcasts | Spotify | RSS
During the Asia-focused Episode 37 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key trends from the 2026 Q2
Podcast: Play in new window | Download (Duration: 12:10 — 27.8MB)
Subscribe: Apple Podcasts | Spotify | RSS
During Episode 36 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q2 Report: Global Trends in Biopharma
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q2 Report applies the latest data to analyze the current landscape in life sciences deals.
LOCUST WALK NEWS Tearing Off the “China Discount”: How Can Chinese Innovative-Drug BD Deals Sell at Their True Worth? July